Baseline and clinical characteristics of 50 evaluable participants in the iCARE1 clinical study
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 66.5 (42-90) |
| Sex | |
| Female | 25 (50) |
| Male | 25 (50) |
| Disease and origin | |
| MDS | 15 (30) |
| AML | 33 (66) |
| De novo | 21 (64) |
| Secondary | 12 (36) |
| CMML-2 | 1 (2) |
| Myelofibrosis | 1 (2) |
| Diagnosis | |
| Newly diagnosed | 34 (68) |
| Relapsed/refractory | 16 (32) |
| Prior therapy | |
| No | 20 (40) |
| Yes | 30 (60) |
| Cytogenetics | |
| Uninformative | 17 (34) |
| Complex | 31 (62) |
| Other | 2 (4) |
| Characteristics . | Data . |
|---|---|
| Age, median (range), y | 66.5 (42-90) |
| Sex | |
| Female | 25 (50) |
| Male | 25 (50) |
| Disease and origin | |
| MDS | 15 (30) |
| AML | 33 (66) |
| De novo | 21 (64) |
| Secondary | 12 (36) |
| CMML-2 | 1 (2) |
| Myelofibrosis | 1 (2) |
| Diagnosis | |
| Newly diagnosed | 34 (68) |
| Relapsed/refractory | 16 (32) |
| Prior therapy | |
| No | 20 (40) |
| Yes | 30 (60) |
| Cytogenetics | |
| Uninformative | 17 (34) |
| Complex | 31 (62) |
| Other | 2 (4) |
Unless otherwise noted, all data are n (%).
CMML-2, chronic myelomonocytic leukemia-2.